×
Obinutuzumab Provides Two-Year Benefits for Lupus Nephritis
https://www.hcplive.com/view/obinutuzumab-two-year-benefits-lupus-nephritis

Nov 3rd, 2020 - After promising 18-month outcomes in patients with proliferative lupus nephritis, obinutuzumab showed sustained benefits through 2 years of treatment for patients burdened with the rheumatic disease.

Machine Learning Could Benefit Rheumatoid Arthritis Treatment with Sarilumab
https://www.hcplive.com/view/machine-learning-benefit-rheumatoid-arthritis-treatment-sarilumab

Nov 2nd, 2020 - As interleukin receptor (IL) inhibitors, the monoclonal antibody drug class has come to revolutionize fields of inflammatory disease care, though the utility and resourcing of such promising agents is yet to be fully refined. Namely, clinicians can stand to benefit from more biomarkers, more indications by which monoclonal antibodies are most impactful.

Workplace flexibility significantly impacts employment for patients with RA
https://www.healio.com/rheumatology/rheumatoid-arthritis/news/online/%7B21372e0e-c397-4c8a-8a9d-0541963b3956%7D/workplace-flexibility-significantly-impacts-employment-for-patients-with-ra

Nov 9th, 2018 - Less flexible work arrangements and more physically demanding jobs were linked to a higher unemployment rate among patients with rheumatoid arthritis, according to data presented at the ACR/ARHP 2018 Annual Meeting.

AVERT-2 fails to meet primary endpoint, but data advances the field for RA
https://www.healio.com/rheumatology/rheumatoid-arthritis/news/online/%7B5fe7c1bb-81f5-48a0-b039-c418a616a55d%7D/avert-2-fails-to-meet-primary-endpoint-but-data-advances-the-field-for-ra

Nov 6th, 2018 - Although the AVERT-2 study failed to meet the primary endpoint of a statistically significant difference in SDAI ≤3.3 at 24 weeks, Sheila Kelly, MD, the medical team lead for immunoscience at Bristol-Myers Squibb, sat down with Healio Rheumatology to discuss how the results have nevertheless provided new insight into treatment with abatacept in patients with newly diagnosed ACPA-positive rheuma...

Genetic testing decoded: Discussing goals, limitations of direct-to-consumer tests
https://www.healio.com/rheumatology/practice-management/news/online/%7B20161761-e5e2-44ba-b340-c5fb26b75e45%7D/genetic-testing-decoded-discussing-goals-limitations-of-direct-to-consumer-tests

Nov 1st, 2018 - In light of the explosive popularity of direct-to-consumer genetic testing and its impact on the conversations between physicians and their patients, Timothy B. Niewold, MD, director of the Colton Center for Autoimmunity at NYU Langone Health, sat down with Healio Rheumatology to discuss how rheumatologists can interpret these genetic reports and better manage the expectations of their patients.

Half of patients with RA do not modify therapies to meet treat-to-target guidelines
https://www.healio.com/rheumatology/rheumatoid-arthritis/news/online/%7B74c5d0ed-964e-4832-8708-a53404564028%7D/baricitinib-maintains-safety-profile-in-ra-shows-promise-for-lupus

Oct 31st, 2018 - Terence Rooney, MD, senior medical director for Eli Lilly, highlights recent findings from an updated integrated safety analysis of baricitinib from a long-term study of patients with rheumatoid arthritis treated up to six years.

‘Be Fierce. Take Control.’ campaign tackles racial disparity in lupus diagnosis
https://www.healio.com/rheumatology/lupus/news/online/%7B93103979-8ca0-4fec-8095-39f58db01195%7D/be-fierce-take-control-campaign-tackles-racial-disparity-in-lupus-diagnosis

Oct 26th, 2018 - In an effort to diminish time-to-diagnosis among black and Latino women at elevated risk for lupus, the ACR and the Lupus Foundation of America unveiled at the ACR/ARHP 2018 annual meeting, a digital campaign intended to raise awareness of lupus in these at-risk populations and provide information on what these women should do next.

Sustained Joint and Skin Improvement Found With Bimekizumab in Psoriatic Arthritis
https://www.rheumatologyadvisor.com/home/conference-highlights/acr-2018-coverage/sustained-joint-and-skin-improvement-found-with-bimekizumab-in-psoriatic-arthritis/

Oct 24th, 2018 - Christopher T. Ritchlin, MD, MPH, University of Rochester Medical Center, discusses updated bimekizumab data from the BE-ACTIVE trial presented at the 2018 ACR/ARHP Annual Meeting, held October 19-24, in Chicago, Illinois.

Hundredfold increase in hospitalizations among gout patients underscores disease burden
https://www.healio.com/rheumatology/gout/news/online/%7B96c72669-97d3-4cc6-832d-396e93e09ec9%7D/hundredfold-increase-in-hospitalizations-among-gout-patients-underscores-disease-burden

Oct 23rd, 2018 - All-cause hospitalization increased 410% among patients with gout during the last 22 years, nearly 100 times more than the overall population in the United States, according to findings presented during the ACR/ARHP Annual Meeting.